NASDAQ:BDTX Black Diamond Therapeutics Q3 2026 Earnings Results & Report $1.60 -0.27 (-14.25%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Black Diamond Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.17 versus the -$0.0938 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeAfter Market ClosesConference Call7:00 AM ET Black Diamond Therapeutics EPS ResultsActual EPS-$0.17Consensus EPS -$0.0938Beat/MissMissed by -$0.0763One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersBlack Diamond Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$8.33 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Black Diamond Therapeutics Q3 2026 Earnings FAQ Did Black Diamond Therapeutics beat earnings estimates for Q3 2026? Black Diamond Therapeutics (NASDAQ:BDTX) reported earnings of -$0.17 per share for Q3 2026, missing the consensus estimate of -$0.0938. The report was announced on Tuesday, November 10, 2026. Black Diamond Therapeutics Earnings HeadlinesBlack Diamond Posts Strong Silevertinib Data; FDA Supports Phase 3 Path; Shares RiseNovember 10 at 10:10 AM | rttnews.comBlack Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10 at 10:10 AM | marketscreener.comMToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and ...November 10 at 10:10 AM | finance.yahoo.comBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate UpdateNovember 10 at 6:30 AM | globenewswire.comBlack Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in ...November 9 at 7:19 PM | finance.yahoo.comSee More Black Diamond Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Black Diamond Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Diamond Therapeutics and other key companies, straight to your email. Email Address About Black Diamond TherapeuticsBlack Diamond Therapeutics (NASDAQ:BDTX) is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches. Black Diamond’s pipeline has included brain-penetrant therapies for cancers affecting the central nervous system. Its lead programs have focused on molecularly targeted treatments such as BDTX-1535, an investigational EGFR inhibitor being evaluated in cancers with specific EGFR alterations, and BDTX-4933, an investigational pan-RAF inhibitor intended to target tumors driven by aberrant MAPK pathway signaling. These programs are being studied in clinical trials, and their safety and effectiveness have not been established for marketing. Founded in 2017 and headquartered in Cambridge, Massachusetts, Black Diamond conducts research and clinical development activities aimed at serving patients with biomarker-defined solid tumors. The company is led by Mark V. Glickman, who serves as chief executive officer. Black Diamond Therapeutics trades on the Nasdaq under the symbol BDTX.View Black Diamond Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
